Abstract:Strategies that hijack selective proteins of interest (POIs) to the intracellular protein recycling machinery for targeted protein degradation (TPD) have recently emerged as powerful tools for undruggable targets in biomedical research and the pharmaceutical industry. However, targeting any new POI with current TPD tools requires laborious case-by-case design for different diseases and cell types, especially for those extracellular targets. Here, we observed that nanoparticles (NPs) can mediate the receptor-free internalization of hijacked protein and further developed a generic paradigm for both intra- and extracellular POI degradation, by making full use of clinically approved components. The phenomenon is general, as we found nanostructures such as lipid nanoparticle (LNP), liposomes, exosomes, polymeric nanoparticles, inorganic nanoparticles and their hybrid nanoparticles modified with POI-recognizing moiety (antibody, peptides, small molecule drugs) can mediate TPD for a wide range of extracellular/membrane and intracellular targets. The super flexible and feasible-to-synthesize TPD-NPs paradigm may revolutionize the current TPD tools development landscape and it provides fundamental knowledge to receptor mediated drug therapies.HighlightsNanoparticle mediated targeted protein degradation (TPD-NP) can be constructed by “Mix-and-Match” and do not require de novo synthesis or specific internalization design.TPD-NPs can be equipped with specific cell type targeting capacity, loading and controlled release of therapeutic cargos, as well as biological barrier penetration capacity.Assembling components can be clinical …

Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells

Bifunctional small molecules that mediate the degradation of extracellular proteins

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?

New therapies on the horizon: Targeted protein degradation in neuroscience

Targeted protein degradation in drug development: Recent advances and future challenges

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation directly engaging lysosomes or proteasomes

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Targeted protein degradation: current molecular targets, localization, and strategies

Targeted protein degradation: from mechanisms to clinic

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Bifunctional modalities for repurposing protein function

Targeted Protein Degradation via Nanoparticles

Targeted protein degradation: mechanisms, strategies and application

Autophagy‐mediated targeted protein degradation

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Degradation of Extracellular and Membrane Proteins in Targeted Therapy: Status Quo and Quo Vadis.

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions